Lilly Ventures Lilly Ventures Home Our Story Our Portfolio Our Team News Contact Us Our Story Lilly Ventures has its roots in the scientific tradition of Eli Lilly and Company. Our investment philosophy drives us to seek great companies with compelling life science innovations. Our Team Our collaborative partnership leverages the collective experience, deep expertise, and networks of our investment professionals for the benefit of our portfolio companies. Our Portfolio Our News Aileron appoints Vice President of Clinical Development September 06 2012 Aileron Therapeutics, Inc. announced the appointment of Hubert C. Chen, M.D., to Vice President of Clinical Development, Endocrine and Metabolic Disease. view full story FORMA Therapeutics appoints Chief Business Officer September 05 2012 FORMA Therapeutics announced the appointment of Rob Sarisky, Ph.D. to Chief Business Officer. Dr. Sarisky most recently served as Vice President of Oncology Business Development and Licensing at Janssen Pharmaceuticals. view full story Cerulean Announces First Patient Dosed in Phase 2 Study in Ovarian Cancer July 23 2012 Cerulean Pharma Inc. announced that the first patient has been dosed in a Phase 2 study of its lead candidate, CRLX101, in platinum-resistant ovarian cancer patients. view full story Receptos Publishes G-Protein Coupled Receptor Structure in Science July 12 2012 Receptos Inc. announced the co-publication, with The Scripps Research Institute, of high resolution G-protein coupled receptor (GPCR) crystal structures in Science. This will enable rational drug discovery and design of GPCRs. view full story Cerulean Completes Enrollment of Phase 2 Study in Non-Small Cell Lung Cancer July 02 2012 Cerulean Pharma Inc. announced that it has completed enrollment of a randomized Phase 2 study of its lead candidate, CRLX101, in advanced non-small cell lung cancer (NSCLC) patients. view full story Cerulean Announces First Patient Dosed in Phase 1b/2a Study in Combination with Avastin in Renal Cancer July 02 2012 Cerulean Pharma Inc. announced the first patient has been dosed in a Phase 1b/2a study of its lead product candidate, CRLX101, in combination with Avastin, in metastatic renal cell carcinoma (mRCC) patients. view full story FORMA Therapeutics Partners with TGen Drug Development (TD2) July 02 2012 FORMA Therapeutics and TGen Drug Development (TD2) announced an agreement to jointly develop transformative cancer therapies, leveraging the synergistic capabilities of both organizations. view full story Viamet Pharmaceuticals Announces Agreement with NIAID June 19 2012 Viamet Pharmaceuticals, Inc. announced that it has entered into a Non-Clinical Evaluation Agreement with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). Under this agreement, Viamet will utilize NIAIDs preclinical services program to develop broad-spectrum antifungal agents. view full story Protagonist Therapeutics and Zealand Pharma Enter Drug Discovery Collaboration June 18 2012 Protagonist entered into a collaboration agreement with Zealand Pharma to identify novel peptide drug candidates by utilizing Zealand Pharmas expertise in peptide optimization technology. view full story Sutro Closes $16.5 Million Second Tranche of Series C Financing May 08 2012 Sutro Biopharma announced the closing of the $16.5 million second tranche of its Series C financing. This funding will be utilized to develop next generation antibody drug conjugates and bi-specific antibody platforms. view full story Viamet Pharmaceuticals Appoints Chief Business and Financial Officer March 07 2012 Viamet Pharmaceuticals, Inc. announced the appointment of Richard D. Katz, M.D. to the newly created position of Chief Business and Financial Officer. Dr. Katz will be responsible for strategic planning and direction, overseeing commercial and financial operations and execution of the companys corporate and business development activities. view full story Hydra and Zalicus Collaborate on Novel Ion Channel Candidates for the Treatment of Pain February 09 2012 Zalicus Inc. and Hydra Biosciences, Inc. announced that they have entered into a collaboration to advance development of Zalicus preclinical ion channel modulator product candidates for the treatment of pain. view full story Cerulean Pharma Appoints Chief Business Officer January 23 2012 Cerulean Pharma Inc., a leader in designing and developing tumor-targeted nanopharmaceuticals, today announced the appointment of Chris Guiffre as Senior Vice President and Chief Business Officer, a newly created position. view full story FORMA Therapeutics Announces Drug Discovery Alliance With Janssen Biotech January 10 2012 FORMA Therapeutics today announced an exclusive alliance with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies, in which the two companies will collaborate on the discovery, development and commercialization of novel small molecule drug candidates that target tumor metabolism mechanisms. view full story Hydra Biosciences and Cubist Pharmaceuticals Announce Plans to Initiate Phase 1 Trial for Novel TRPA1 Modulator January 10 2012 Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) and Hydra Biosciences, Inc. today announced plans to begin a Phase 1 clinical trial for a small molecule antagonist of the human Transient Receptor Potential Ankyrin repeat 1 (TRPA1) ion channel discovered in a collaboration between Cubist and Hydra. view full story Sutro Biopharma Announces Newly Formed Scientific Advisory Board January 07 2012 Sutro Biopharma appointed James A. Wells, Ph.D., who has a depth of expertise and defining experience in protein engineering, and James R. Swartz, Sc.D., a leading expert in the field of cell-free protein synthesis, to the Sutro Scientific Advisory Board. Dr. Wells will serve as Chairman of the SAB view full story FORMA Therapeutics Announces Collaboration with Boehringer Ingelheim January 05 2012 FORMA Therapeutics announced a research and development collaboration with Boehringer Ingelheim to discover and develop novel drug candidates for the treatment of cancer. view full story Viamet Initiates Phase 1 Prostate Cancer Clinical Trial January 04 2012 Viamet Pharmaceuticals, Inc., announced that dosing has begun in a Phase 1/2 clinical trial of VT-464, an oral, potent and lyase-selective CYP17 inhibitor for the treatment of castration-refractory prostate cancer (CRPC). VT-464 is a novel, non-steroidal, small molecule discovered by Viamet Pharmaceuticals using its proprietary Metallophile® Technology. view full story Receptos and Ono Establish Collaboration on Bioactive Lipid Discovery Research December 12 2011 Receptos Inc. announced the establishment of a collaboration with Ono Pharmaceutical Co., Ltd. (Osaka, Japan) for the research and development of small molecule modulators of an undisclosed Gprotein coupled receptor (GPCR) target. Under the terms of the agreement, Receptos will use its proprietary technology platform to produce high resolution protein crystal structures of the discovery target and drive Onos structurebased drug design efforts. view full story Aileron Announces Expansion of Roche Collaboration November 16 2011 Aileron Therapeutics, Inc. announced the expansion of an existing drug discovery collaboration with Roche adding a third target in inflammatory disease to the existing oncology targets. view full story Cerulean Pharma Presents Phase 1/2a Lung Cancer Clinical Study of CRLX101 November 14 2011 Cerulean Pharma presented final data from the non-small cell lung cancer Phase 1/2a clinical study of CRLX101 at the AACR-NCI-EORTC conference. The drug was well tolerated at the maximum tolerated dose (MTD) and provided encouraging progression free survival (PFS) times. view full story Viamet Appoints Chief Medical Officer November 03 2011 Viamet Pharmaceuticals Appoints Former Novartis Executive Marc Rudoltz, M.D. as Chief Medical Officer. view full story Gilead Licenses GlobeImmune HBV Program October 24 2011 GlobeImmune and Gilead Announce Hepatitis B License and Collaboration Agreement. view full story Viamet Initiates Antifungal Clinical Trials September 14 2011 Viamet Pharmaceuticals Initiates Phase 1 Clinical Trials for Best-in-Class Novel Antifungal VT-1161. view full story Forma Therapeutics Named One of the "Fierce 15" Leading Biotech Companies in 2011 September 06 2011 FORMA Therapeutics was named by FierceBiotech as one of the 2011 Fierce 15, designating it as one of the most promising private biotechnology companies in the industry. view full story Cerulean Pharma Named One of the Fierce 15 Leading Biotech Companies of 2011 September 06 2011 Cerulean Pharma Inc., a leader in designing and developing tumor-targeted nanopharmaceuticals, announced that FierceBiotech has named the Company one of 2011's Fierce 15 companies, designating it as one of the most promising private biotechnology companies in the industry. view full story Viamet and NIH to Develop Novel Anti-Fungal July 28 2011 Viamet anti-fungal program was selected for inclusion by the National Institutes of Health program for Therapeutics for Rare and Neglected Diseases (TRND) Program. view full story Cerulean Initiates Randomized Phase 2 of CRLX101 in Non-Small Cell Lung Cancer July 12 2011 Cerulean Pharma Inc., a leader in designing and developing tumor-targeted nanopharmaceuticals, today announced the dosing of the first patients with CRLX101 in a randomized, controlled non-small cell lung cancer (NSCLC) Phase 2 clinical trial. view full story Receptos Hires Industry Veteran as Chief Medical Officer June 30 2011 Sheila Gujrathi, M.D., joins Receptos as Chief Medical Officer from Bristol-Meyers Squibb. view full story Nimbus Discovery Secures $24MM Series A Financing June 28 2011 Nimbus Discovery LLC, a biopharmaceutical company using state-of-the-art computational technology to discover novel medicines against exciting but previously inaccessible disease targets, today announced the close of a $24MM Series A financing. The investment was co-led by Atlas Venture, Lilly Ventures, and SR One. view full story FORMA Therapeutics Grants Genentech Exclusive Rights to Acquire a Pre-clinical Cancer Program June 27 2011 FORMA Therapeutics announced today that it entered into an agreement granting Genentech, a member of the Roche Group, exclusive worldwide rights to acquire a pre-clinical small molecule program against a single undisclosed cancer target. view full story GlobeImmune Reports Positive Results on Two Therapeutic Cancer Vaccines June 01 2011 GlobeImmune announces safety and immunogenicity data from clinical trials in lung cancer with KRAS mutations and CEA expressing cancers. view full story Sutro's Biochemical Protein Synthesis Technology Enables Rapid Production and Scale-Up May 19 2011 Sutro Biopharma, which is developing novel and biosuperior protein therapeutics with improved pharmaceutical properties, announced that a study published in the July issue of Biotechnology and Bioengineering demonstrates that the companys biochemical protein synthesis technology platform enables fast and high-yield protein synthesis, scale-up, and straightforward purification by producing a fully bioactive, human, cytokine at titers of 700 mg/L in only 10 hours. view full story Cerulean Pharma Appoints Chief Medical Officer May 17 2011 Cerulean Pharma Inc. appoints Edward Garmey, M.D. to serve as Chief Medical Officer and Senior Vice President. view full story Aileron Adds Industry R D Veterans April 11 2011 Aileron hires industry veteran Anthony Manning, Ph.D. as Senior Vice President of Research and Preclinical Development. view full story Cerulean Presents Phase 2a Oncology Clinical Data at AACR April 04 2011 Cerulean presents Phase 2a interim clinical data that highlight observations of stable disease in advanced non-small cell lung carcinoma (NSCLC) patients. view full story Receptos Initiated Phase 1 Clinical Trial January 27 2011 Receptos, Inc., announced today that their highly selective sphingosine-1-phosphate receptor 1 (S1P1) agonist, RPC1063, has been administered to the first subject in a single-ascending and multiple-ascending dose design Phase 1 clinical safety study. view full story Former FDA Commissioner Joins Viamet Board January 19 2011 Andrew von Eschenbach, M.D., Former FDA Commissioner and Leading Prostate Cancer Expert, Elected to Viamet Pharmaceuticals Board of Directors. view full story Protagonist Establishes Partnership with Ironwood Pharmaceuticals January 18 2011 Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Protagonist Therapeutics, Inc. announced that they have entered into a collaboration to discover novel peptides for potential development by Ironwood. The collaboration capitalizes on Protagonist's proprietary disulfide rich peptide (DRP) technology platform, and provides Ironwood with the opportunity to develop novel peptides and treatments against clinicallyvalidated targets in therapeutic areas with significant unmet medical needs. view full story Sutro Biopharma Forges Partnership with Pfizer January 07 2011 Sutro Biopharma enters into a multiyear collaboration with Pfizer for the research, development and commercialization of novel peptide-based therapeutics. view full story Receptos in Exclusive Collaboration with Eli Lilly and Company January 06 2011 Receptos announced an exclusive collaboration focused on structure determination and lead generation for a high value G-protein Coupled Receptor (GPCR) target. view full story Avid Closing Press Release December 20 2010 Avid acquisition closes. view full story Sutro Biopharma Appoints Trevor Hallam, Ph.D., as Chief Scientific Officer December 08 2010 Sutro Biopharma today announced that it has appointed Trevor Hallam, Ph.D., as Chief Scientific Officer (CSO). Dr. Hallam will lead Sutro's ongoing efforts in the application of the company's proprietary protein biochemical synthesis platform for the research and development of novel and biosuperior therapeutics. view full story Faheem Hasnain Named President and Chief Executive Officer of Receptos December 02 2010 Industry veteran will strengthen Receptoss clinical and commercial expertise in multiple sclerosis and expand activities including the potential to acquire additional focused therapeutic assets. view full story Eisai and FORMA Therapeutics Enter into Broad Drug Discovery Collaboration November 17 2010 Eisai and FORMA Therapeutics announced a strategic drug discovery collaboration. Eisai will have non-exclusive access to FORMA's Diversity Oriented Synthesis (DOS) chemistry-generated compound library and cell-based screening platforms to support the discovery of novel compounds for Eisai's pipeline and an option for technology transfer of FORMA's cell-based screening platform. view full story GlobeImmune Announces Improves HCV End of Treatment Response in Phase 2b October 20 2010 GlobeImmune Announces HCV End of Treatment Response in Phase 2b view full story Roche and Aileron Multi-target Deal August 24 2010 Roche enters $1.1B deal with Aileron on up to five undisclosed targets in oncology, virology, inflammation, metabolism and central nervous system. view full story CGI to be Acquired by Gilead Sciences July 14 2010 Gilead Science and CGI announce the signing of a Definitive Agreement whereby Gilead will acquire CGI. view full story Viamet Appoints Bill Moore as CSO January 11 2010 Announced today that William Moore, Ph.D. has joined the company as Chief Scientific Officer. view full story Intradigm Merges with Silence Therapeutics January 05 2010 Silence Therapeutics plc (the Company) (AIM: SLN) and Intradigm Corporation announce that the companies have completed their merger to form a leading company in the field of RNAi (RNA interference). view full story Home | Our Story | Our Portfolio | Our Team | News | Contact Us Copyright © 2016 Lilly Ventures Management Company, LLC. All rights reserved.